亚博下载app-安卓版下载

English
Company profile/Product
Products in Research

Academic efforts to understand the factors contributing to responsiveness to checkpoint inhibitors have supported the therapeutic approaches used by OncoVent. Studies have retrospectively shown that patients with tumor germ line mutations causing neo-antigen expression and tumors exhibiting specific patterns of infiltrating inflammatory cells awe more likely to benefit from checkpoint inhibition OncoVent's approach seeks to generate immunity for all patients, but especially for those whose tumors are otherwise insufficiently immunogenic. The company’s immunoglobulin-γ (IgG) technology induces cellular immunity to otherwise immune silent tumor antigen and its IgE technology works by the same mechanism while also modulating the tumor stroma directly.


The company is using tumor antigen-specific monoclonal antibodies, in conjunction with selective immune stimulants and the coordinated use of selected cytotoxics, to generate higher background of immune response, which can then be released with checkpoint inhibition.



IgG
Oregovomab (MAb B43.13)
The company’s leadproduct is oregovomab, an IgG monoclonal antibody that targets a tumor antigencalled MUC16 (CA 125) Oregovomab is currently being evaluated in combinationwith chemotherapy in phase 2 clinical studies of people with advanced ovariancancer
Oregovomab (MAb B43.13)
AR20.5
OncoVent is alsodeveloping AR20.5, another IgG monoclonal antibody that targets MUC1, a commontumor antigen. This antibody has the potential to permit tumor-specificimmunization in most mucinous epithelial cancers.
AR20.5
IgE
IgE Immunotherapy
OncoVentspreclinical program is focused on the development of second-generation IgE antibodies
IgE Immunotherapy
View more+